Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eliquis

- PMLiVE

Nektar confirms BMS deal for NKTR-214 is on track

Shares in Nektar rose 10% in the wake of the presentation at JPM healthcare conference

- PMLiVE

BMS and Celgene deal sparks debate on pharma profit motive, more M&A

Biopharma backlash at Warren tweet, but Celgene tactics in the spotlight

Celgene building

BMS and Celgene announce $74bn merger

Huge news for sector, with new fourth-placed company to be created

- PMLiVE

BMS to test Vedanta’s bacterial therapy with Opdivo

Will be trialled in those with advanced or metastatic cancers

- PMLiVE

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

But it is only available via the CDF for now

- PMLiVE

FDA green lights BMS’ multiple myeloma combo

Speedy approval follows a breakthrough designation

- PMLiVE

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma

- PMLiVE

BMS finds a new immunotherapy partner with $12m Compugen deal

Combination with novel antibody targeting PVRIG pathway

Bristol Myers Squibb logo

BMS psoriasis drug hits the mark in phase II

Tyrosine kinase 2 (Tyk2) inhibitors could play major role

- PMLiVE

NICE turns down Opdivo for adjuvant melanoma therapy

BMS drug currently only licensed treatment in this setting

- PMLiVE

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

Becomes the first checkpoint inhibitor for this indication

- PMLiVE

Daily Brief: European approvals for BMS’ Opdivo, Aegerion’s lipodystrophy treatment, Pfizer’s biosimilar and Xeljanz

Will Pfizer spark price war with its Herceptin biosimilar?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links